Page last updated: 2024-12-10

2-(3-oxo-2,4-dihydro-1H-quinoxalin-2-yl)-N-phenylacetamide

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Let's break down the compound 2-(3-oxo-2,4-dihydro-1H-quinoxalin-2-yl)-N-phenylacetamide and its research significance:

**Understanding the Structure**

* **Core Structure:** The base of this compound is a quinoxaline ring system. Quinoxalines are heterocyclic compounds containing a nitrogen atom at position 1 and another at position 5 in a benzene ring.
* **Substituents:**
* **3-oxo:** A carbonyl group (C=O) is attached to the carbon at position 3 on the quinoxaline ring. This carbonyl group makes the compound a ketone.
* **2,4-dihydro:** This indicates that the compound contains a hydrogen atom at position 2 and another at position 4 on the quinoxaline ring. These hydrogen atoms suggest the presence of double bonds in the ring structure.
* **1H:** This indicates a hydrogen atom at position 1 on the quinoxaline ring.
* **2-(...)-N-phenylacetamide:** This tells us that the quinoxaline ring is attached to a phenylacetamide group at position 2. The phenylacetamide group is a combination of an acetamide (CH3CONH2) and a phenyl (C6H5) group.

**Importance in Research**

While the exact research focus is not clear from just the chemical name, compounds like this are often explored for their potential biological activities. Here's why they might be important:

* **Pharmacological Activity:** Quinoxalines and their derivatives have shown a wide range of pharmacological activities, including:
* **Anti-cancer:** They might interfere with the growth and development of cancerous cells.
* **Anti-microbial:** They could inhibit the growth of bacteria and fungi.
* **Anti-inflammatory:** They might reduce inflammation and pain.
* **Cardiovascular activity:** They could affect heart function and blood pressure.
* **Structure-Activity Relationships:** Chemists study how modifications to the structure of molecules affect their biological activities. Understanding the relationship between structure and activity is crucial for designing new and more effective drugs.
* **Lead Compounds:** A compound like this might act as a lead compound for further development. Researchers might modify its structure to create derivatives with enhanced activity or improved safety profiles.

**Further Research:**

To fully understand the significance of 2-(3-oxo-2,4-dihydro-1H-quinoxalin-2-yl)-N-phenylacetamide, you would need to look into:

* **Specific Research Publications:** Searching scientific databases (e.g., PubMed, Scopus) using the compound name or related keywords would reveal published studies on its properties.
* **Current Research Projects:** You could search for ongoing research projects involving this compound.

**In summary,** the compound 2-(3-oxo-2,4-dihydro-1H-quinoxalin-2-yl)-N-phenylacetamide is likely being investigated for its potential therapeutic applications due to the known biological activities of quinoxaline derivatives.

Cross-References

ID SourceID
PubMed CID2829724
CHEMBL ID1486416
CHEBI ID116650

Synonyms (34)

Synonym
REGID4257301
BB 0242762
2-(3-oxo-1,2,3,4-tetrahydro-quinoxalin-2-yl)- n-phenyl-acetamide
IDI1_008405
IFLAB1_000186
CBDIVE_001778
OPREA1_517910
smr000071674
MLS000062987
2-(3-oxo-1,2,3,4-tetrahydro-2-quinoxalinyl)-n-phenylacetamide
OPREA1_656041
STK252143
2-(3-oxo-1,2,3,4-tetrahydroquinoxalin-2-yl)-n-phenylacetamide
CHEBI:116650
2-(3-oxo-2,4-dihydro-1h-quinoxalin-2-yl)-n-phenylacetamide
HMS1412I10
AKOS002251528
2-(3-oxo-1,2,3,4-tetrahydro-quinoxalin-2-yl)-n-phenyl-acetamide
36932-40-8
EN300-06253
AKOS016318189
AB00074357-01
CHEMBL1486416
F0016-0151
cambridge id 5141035
acetamide. 2-(3-oxo-1,2,3,4-tetrahydroquinoxalin-2-yl)-n-phenyl-
KJTNMDRAZRYXNY-UHFFFAOYSA-N
Z31269300
DTXSID10385254
Q27200955
sr-01000396953
SR-01000396953-1
mfcd00226058
CS-0349510
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Drug Classes (1)

ClassDescription
amino acid amideAn amide of an amino acid formed formally by conversion of the carboxy group to a carboxamido group.
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Protein Targets (26)

Potency Measurements

ProteinTaxonomyMeasurementAverage (µ)Min (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Chain A, HADH2 proteinHomo sapiens (human)Potency25.11890.025120.237639.8107AID893
Chain B, HADH2 proteinHomo sapiens (human)Potency25.11890.025120.237639.8107AID893
Chain A, 2-oxoglutarate OxygenaseHomo sapiens (human)Potency35.48130.177814.390939.8107AID2147
Chain A, CruzipainTrypanosoma cruziPotency12.58930.002014.677939.8107AID1476
LuciferasePhotinus pyralis (common eastern firefly)Potency21.33130.007215.758889.3584AID588342
acid sphingomyelinaseHomo sapiens (human)Potency25.118914.125424.061339.8107AID504937
thioredoxin reductaseRattus norvegicus (Norway rat)Potency70.79460.100020.879379.4328AID588453
ATAD5 protein, partialHomo sapiens (human)Potency16.36010.004110.890331.5287AID504467
TDP1 proteinHomo sapiens (human)Potency29.09290.000811.382244.6684AID686978; AID686979
Microtubule-associated protein tauHomo sapiens (human)Potency22.38720.180013.557439.8107AID1460
thioredoxin glutathione reductaseSchistosoma mansoniPotency50.11870.100022.9075100.0000AID485364
Smad3Homo sapiens (human)Potency11.22020.00527.809829.0929AID588855
aldehyde dehydrogenase 1 family, member A1Homo sapiens (human)Potency39.81070.011212.4002100.0000AID1030
P53Homo sapiens (human)Potency22.38720.07319.685831.6228AID504706
heat shock 70kDa protein 5 (glucose-regulated protein, 78kDa)Homo sapiens (human)Potency50.11870.016525.307841.3999AID602332
nuclear factor erythroid 2-related factor 2 isoform 2Homo sapiens (human)Potency3.66260.00419.984825.9290AID504444
importin subunit beta-1 isoform 1Homo sapiens (human)Potency57.29055.804836.130665.1308AID540253; AID540263
ras-related protein Rab-9AHomo sapiens (human)Potency6.30960.00022.621531.4954AID485297
snurportin-1Homo sapiens (human)Potency57.29055.804836.130665.1308AID540253; AID540263
peptidyl-prolyl cis-trans isomerase NIMA-interacting 1Homo sapiens (human)Potency67.45550.425612.059128.1838AID504891
GTP-binding nuclear protein Ran isoform 1Homo sapiens (human)Potency14.58105.804816.996225.9290AID540253
DNA polymerase iota isoform a (long)Homo sapiens (human)Potency89.12510.050127.073689.1251AID588590
nuclear receptor ROR-gamma isoform 1Mus musculus (house mouse)Potency20.24660.00798.23321,122.0200AID2546; AID2551
gemininHomo sapiens (human)Potency9.55120.004611.374133.4983AID624296; AID624297
DNA dC->dU-editing enzyme APOBEC-3G isoform 1Homo sapiens (human)Potency12.58930.058010.694926.6086AID602310
DNA dC->dU-editing enzyme APOBEC-3F isoform aHomo sapiens (human)Potency12.58930.025911.239831.6228AID602313
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Bioassays (17)

Assay IDTitleYearJournalArticle
AID588497High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set2010Current protocols in cytometry, Oct, Volume: Chapter 13Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588497High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set2006Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588497High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set2010Assay and drug development technologies, Feb, Volume: 8, Issue:1
High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID504812Inverse Agonists of the Thyroid Stimulating Hormone Receptor: HTS campaign2010Endocrinology, Jul, Volume: 151, Issue:7
A small molecule inverse agonist for the human thyroid-stimulating hormone receptor.
AID588499High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set2010Current protocols in cytometry, Oct, Volume: Chapter 13Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588499High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set2006Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588499High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set2010Assay and drug development technologies, Feb, Volume: 8, Issue:1
High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID588501High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set2010Current protocols in cytometry, Oct, Volume: Chapter 13Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588501High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set2006Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588501High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set2010Assay and drug development technologies, Feb, Volume: 8, Issue:1
High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID504810Antagonists of the Thyroid Stimulating Hormone Receptor: HTS campaign2010Endocrinology, Jul, Volume: 151, Issue:7
A small molecule inverse agonist for the human thyroid-stimulating hormone receptor.
AID651635Viability Counterscreen for Primary qHTS for Inhibitors of ATXN expression
AID1745845Primary qHTS for Inhibitors of ATXN expression
AID1794808Fluorescence-based screening to identify small molecule inhibitors of Plasmodium falciparum apicoplast DNA polymerase (Pf-apPOL).2014Journal of biomolecular screening, Jul, Volume: 19, Issue:6
A High-Throughput Assay to Identify Inhibitors of the Apicoplast DNA Polymerase from Plasmodium falciparum.
AID1794808Fluorescence-based screening to identify small molecule inhibitors of Plasmodium falciparum apicoplast DNA polymerase (Pf-apPOL).
AID1159537qHTS screening for TAG (triacylglycerol) accumulators in algae2017Plant physiology, Aug, Volume: 174, Issue:4
Identification and Metabolite Profiling of Chemical Activators of Lipid Accumulation in Green Algae.
AID652178Confirmed Agonists of Novel Allosteric Modulators of the M1 Muscarinic Receptor2013Molecules (Basel, Switzerland), Jan-08, Volume: 18, Issue:1
Benchmarking ligand-based virtual High-Throughput Screening with the PubChem database.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (9)

TimeframeStudies, This Drug (%)All Drugs %
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's1 (11.11)29.6817
2010's6 (66.67)24.3611
2020's2 (22.22)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 12.14

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index12.14 (24.57)
Research Supply Index2.30 (2.92)
Research Growth Index4.44 (4.65)
Search Engine Demand Index0.00 (26.88)
Search Engine Supply Index0.00 (0.95)

This Compound (12.14)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews0 (0.00%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other9 (100.00%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]